OraSure Technologies, Inc. (NASDAQ:OSUR) has earned an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.89.

Several brokerages have recently issued reports on OSUR. Stephens reissued an “overweight” rating and issued a $19.00 price target (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Jefferies Group LLC boosted their price target on shares of OraSure Technologies from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, June 28th. Canaccord Genuity boosted their price target on shares of OraSure Technologies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, June 28th. Finally, Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Saturday, May 6th.

OraSure Technologies (OSUR) traded up 0.95% during mid-day trading on Monday, hitting $19.19. The stock had a trading volume of 999,279 shares. The company has a 50-day moving average price of $15.30 and a 200 day moving average price of $12.00. The company has a market cap of $1.11 billion, a P/E ratio of 36.76 and a beta of 1.56. OraSure Technologies has a 1-year low of $6.23 and a 1-year high of $19.28.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.04. OraSure Technologies had a net margin of 22.57% and a return on equity of 16.06%. The company had revenue of $32.55 million during the quarter, compared to analyst estimates of $31.19 million. During the same quarter in the previous year, the business earned $0.04 EPS. The firm’s revenue was up 11.9% on a year-over-year basis. Equities research analysts forecast that OraSure Technologies will post $0.43 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/07/17/orasure-technologies-inc-nasdaqosur-given-average-rating-of-buy-by-brokerages.html.

In related news, Director Michael Celano sold 44,962 shares of the company’s stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $14.95, for a total value of $672,181.90. Following the transaction, the director now owns 38,117 shares in the company, valued at approximately $569,849.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Mark L. Kuna sold 36,413 shares of the company’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $15.11, for a total transaction of $550,200.43. Following the completion of the transaction, the senior vice president now owns 92,904 shares in the company, valued at approximately $1,403,779.44. The disclosure for this sale can be found here. Insiders have sold a total of 1,220,134 shares of company stock worth $18,789,795 over the last 90 days. 7.80% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Eqis Capital Management Inc. bought a new position in shares of OraSure Technologies during the second quarter worth approximately $371,000. State of Alaska Department of Revenue raised its position in shares of OraSure Technologies by 85.1% in the second quarter. State of Alaska Department of Revenue now owns 11,401 shares of the medical instruments supplier’s stock worth $196,000 after buying an additional 5,241 shares during the period. Fisher Asset Management LLC raised its position in shares of OraSure Technologies by 35.5% in the second quarter. Fisher Asset Management LLC now owns 682,480 shares of the medical instruments supplier’s stock worth $11,780,000 after buying an additional 178,886 shares during the period. NN Investment Partners Holdings N.V. bought a new position in shares of OraSure Technologies during the second quarter worth approximately $329,000. Finally, Bank of Montreal Can raised its position in shares of OraSure Technologies by 102.8% in the second quarter. Bank of Montreal Can now owns 143,295 shares of the medical instruments supplier’s stock worth $2,472,000 after buying an additional 72,644 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Analyst Recommendations for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.